FDA weighs esketamine for depression
Contact us: podcasts@mdedge.com
- FDA panels back intranasal esketamine for refractory depression. http://bit.ly/2TOKrfp
- ONC aims to help doctors, patients with information sharing in proposed rule. http://bit.ly/2X3SVkP
- Survey: Health care costs unlikely to improve in 2019. http://bit.ly/2SwSIYJ
- Vaccination and antiviral treatment don't lower stroke risk after shingles. http://bit.ly/2tjYQVa
Play
Like
Play Next
Mark Played